Michael Landsittel - Blueprint Medicines Director
| BPMC Stock | USD 88.38 2.29 2.66% |
Director
Mr. Michael Landsittel is Chief Financial Officer of Blueprint Medicines Corporationrationration. He has served as our chief financial officer since January 2019. Mr. Landsittel previously served as our vice president, finance from February 2016 to January 2019 and as our senior director, finance from September 2014 to February 2016. Prior to joining, Mr. Landsittel served as senior director, finance at Algeta from October 2012 to July 2014, as director, finance at Infinity Pharmaceuticals, Inc. from March 2012 to October 2012 and held various business development and strategic planning roles of increasing responsibility at Genzyme from August 2002 to March 2012. Mr. Landsittel began his career at Arthur Andersen LLP, and he earned his certified public accountant license in Illinois since 2019.
| Age | 52 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 45 Sidney Street, Cambridge, MA, United States, 02139 |
| Phone | 617 374 7580 |
| Web | https://www.blueprintmedicines.com |
Latest Insider Transactions
Landsittel received a B.B.A from the University of Michigan and an M.B.A. from the Tuck School of Business at Dartmouth College.Blueprint Medicines Management Efficiency
The company has return on total asset (ROA) of (0.2534) % which means that it has lost $0.2534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5714) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of April 18, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.61. At present, Blueprint Medicines' Other Current Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 784.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mari Cano | Betterware De Mexico | N/A | |
| Clyde Patterson | Home Federal Bancorp | 74 | |
| Frank Cousins | Provident Bancorp | 55 | |
| Scott Lawrence | Home Federal Bancorp | 71 | |
| Mark Harrison | Home Federal Bancorp | 58 | |
| Jay Gould | Provident Bancorp | N/A | |
| Woodus Humphrey | Home Federal Bancorp | 77 | |
| Eduardo Szymanski | Betterware De Mexico | N/A | |
| Richard Peeke | Provident Bancorp | 69 | |
| Timothy Wilhite | Home Federal Bancorp | 48 | |
| Laurie Knapp | Provident Bancorp | 56 | |
| Andres Chevallier | Betterware De Mexico | 40 | |
| Lisa DeStefano | Provident Bancorp | N/A | |
| Wayne Tatro | Provident Bancorp | 72 | |
| Walter Colquitt | Home Federal Bancorp | 72 | |
| David Herndon | Home Federal Bancorp | 79 | |
| Arthur Sullivan | Provident Bancorp | N/A | |
| Thomas Trawick | Home Federal Bancorp | 48 | |
| John Bosen | Provident Bancorp | 49 | |
Management Performance
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 |
Blueprint Medicines Corp Leadership Team
Elected by the shareholders, the Blueprint Medicines' board of directors comprises two types of representatives: Blueprint Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Blueprint. The board's role is to monitor Blueprint Medicines' management team and ensure that shareholders' interests are well served. Blueprint Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Blueprint Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicholas Lydon, Director | ||
| Michael Landsittel, Interim Principal Accounting and Financial Officer and Sr. Director of Fin. | ||
| George Demetri, Independent Director | ||
| Dr MBA, Chief Officer | ||
| Anthony Boral, Senior Vice President - Clinical Development | ||
| Tracey Esq, Chief VP | ||
| Kathryn Haviland, Chief Business Officer | ||
| Jeffrey Albers, President CEO, Director | ||
| Alexis Borisy, Director | ||
| Stephen Knight, Director | ||
| Christopher Murray, Senior Vice President Technical Operations | ||
| Tracey McCain, Executive Vice President Chief Legal Officer, Secretary | ||
| Alexis AM, CoFounder Director | ||
| Daniel Lynch, Chairman of the Board | ||
| Marion Dorsch, Chief Scientific Officer | ||
| Mark Goldberg, Director | ||
| Fouad MD, President Development | ||
| Kristin Hodous, IR Contact Officer | ||
| Charles Rowland, Independent Director | ||
| Ariel Hurley, Principal Accounting Officer | ||
| Christina Rossi, Chief Commercial Officer | ||
| Lonnel Coats, Independent Director | ||
| JD MBA, Ex Chairman | ||
| Jenna Cohen, Director Relations | ||
| Christoph Lengauer, Chief Scientific Officer | ||
| Thilo Schroeder, Director | ||
| Lynn Seely, Director |
Blueprint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Blueprint Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (2.03) % | ||||
| Operating Margin | (1.46) % | ||||
| Current Valuation | 5.33 B | ||||
| Shares Outstanding | 61.23 M | ||||
| Shares Owned By Insiders | 0.85 % | ||||
| Shares Owned By Institutions | 99.15 % | ||||
| Number Of Shares Shorted | 4.37 M | ||||
| Price To Earning | 7.93 X |
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving against Blueprint Stock
| 0.52 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.